Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement

References

• Foye WO, Lemke TL, Williams DA. (2007). Foye's principles of medicinal chemistry, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins.
   Google Scholar
• Frey H, Aakvaag A, Saanum D, Falch J. (1979). Bioavailability of oral testosterone in males. Eur J Clin Pharmacol, 16:345–9.
   PubMed Web of Science ®Google Scholar
• Johnsen SG. (1978). Long-term oral testosterone and liver function. Lancet, 1:50.
   PubMed Web of Science ®Google Scholar
• Köhn FM, Schill WB. (2003). A new oral testosterone undecanoate formulation. World J Urol, 21:311–5.
   PubMed Web of Science ®Google Scholar
• Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJ, . (2003). Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther, 306:925–33.
   PubMed Web of Science ®Google Scholar
• Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. (2003). Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy, 23:319–25.
   PubMed Web of Science ®Google Scholar
• Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. (2007). The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf), 66:579–85.
   PubMed Web of Science ®Google Scholar
• Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, . (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 59:419–26.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–13.
   Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–7.
   Web of Science ®Google Scholar
• Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci, 89:967–78.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. (2001). Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res, 21:215–57.
   PubMed Web of Science ®Google Scholar
• Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. (2006). Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317:82–9.
   PubMed Web of Science ®Google Scholar
• Penkler L, Müller RH, Runge S, Ravelli V. (2003). Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. US patent no. 6,551,619.
   Google Scholar
• Müller RH. (1996). Zetapotential und Partikelladung in der Laborpraxis. Stuttgart: Wissenschaftliche Verlagsges.
   Google Scholar
• Lucks JS, Müller BW, Müller RH. (1990). Inorganic suspensions — interaction with salts and ionic surfactants. Int J Pharm, 58:229–35.
   Google Scholar
• Charman WN, Porter CJH. (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deliv Rev, 19:149–69.
   Web of Science ®Google Scholar
• Porter CJ, Charman WN. (2001). Intestinal lymphatic drug transport: An update. Adv Drug Deliv Rev, 50:61–80.
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Müller RH. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 34:1394–405.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Lippacher A, Jenning V. (2000). Fest-flüssige (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen. PCT/EP00/04565.
   Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54:S131–55.
   PubMed Web of Science ®Google Scholar
• Kutz G. (2001). Kosmetische Emulsionen und Cremes. Augsburg: Verlag für Chemische Industrie.
   Google Scholar
• Muchow M. (2009). Nanostructured carriers for oral drug delivery. PhD thesis, Freie Universität, Berlin, in preparation.
   Google Scholar
• Olbrich C, Kayser O, Müller RH. (2002). Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)—effect of surfactants, storage time and crystallinity. Int J Pharm, 237:119–28.
   PubMed Web of Science ®Google Scholar
• Olbrich C, Mehnert W, Müller RH. (1998). In vitro degradation properties of solid Lipid nanoparticles SLN™     2nd world meeting on pharmaceutics, biopharmaceutics, pharmaceutical technology, APGI/APV, Paris, France, May 25–28.
   Google Scholar
• Olbrich C, Müller RH. (1999). Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm, 180:31–9.
   PubMed Web of Science ®Google Scholar
• Junghanns JU, Müller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine, 3:295–309.
   PubMed Web of Science ®Google Scholar